Treatment efficacy outcome measures at baseline, 6 weeks and 12 weeks
| Mean (SD) | ||||
| BL | 6 weeks | 12 weeks | P value* | |
| Total headache days per month | 24.6 (5.6) | 8.6 (7.8) | 10.6 (7.1) | <0.0001 (BL vs 6 weeks) |
| <0.0001 (BL vs 12 weeks) | ||||
| 0.0004 (6 weeks vs 12 weeks) | ||||
| Migraine days per month | 13.0 (4.7) | 2.3 (2.9) | 3.7 (3.4) | <0.0001 (BL vs 6 weeks) |
| <0.0001 (BL vs 12 weeks) | ||||
| <0.0001 (6 weeks vs 12 weeks) |
Reduction in mean (SD) headache days at 6 weeks compared with BL (8.6 (7.8) days vs 24.6 (5.6) days).
Reduction in mean (SD) headache days at 12 weeks compared with BL (10.6 (7.1) days vs 24.6 (5.6) days).
Reduction in mean (SD) migraine days at 6 weeks compared with BL (2.3 (2.9) days vs 13.0 (4.7) days).
Reduction in mean (SD) migraine days at 12 weeks compared with BL (3.7 (3.4) days vs 13.0 (4.7) days).
*P values stand for significant changes between two time points (one-tail paired t-test).
BL, baseline; SSRIs, selective serotonin reuptake inhibitors.